Management of Moderate to Severe Plaque Psoriasis (Part I): Clinical Update on Antitumor Necrosis Factor Agents
February 2009 | Volume 8 | Issue 2 | Original Article | 147 | Copyright © February 2009
Jeffrey M. Sobell MD, Robert E. Kalb MD, Jeffrey M. Weinberg MD
Psoriasis is an immunologic disorder mediated by T cells and proinﬂammatory cytokines. Novel biologic therapies, targeted at key
pathogenic steps, have been developed and provide efﬁcacy without the potential end-organ toxicity induced by traditional therapies.
The biologic therapies currently approved for treatment of psoriasis are classiﬁed into 2 categories, as deﬁned by their mechanism of
action: inhibition of tumor necrosis factor (TNF) (etanercept, inﬂiximab, adalimumab) and modulation of pathogenic activated T cells
(alefacept, efalizumab). This review has been prepared in 2 parts: Part 1 focuses on anti-TNF agents and includes new data that have
become available through increased clinical experience and use in eligible patients. Part 2 will present new data on T-cell modulators,
new molecules in development, and considerations for optimal therapeutic selection for treatment of patients with psoriasis (Journal
of Drugs in Dermatology, March 2009).